Preclinical antitumor activity of an antibody against the leukocyte antigen CD48

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 895-900

  Sun, Haiping ^a   Norris, Belinda J ^a   Atkinson, Kerry ^b   Biggs, James C ^b   Smith, Glenn M ^a,c  

^a Coop Res Ctr Biopharmaceutical R ^*  (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c CRC for Biopharmaceutical Research   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD48 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN CELL; LYMPHATIC LEUKEMIA; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, NEOPLASM; BINDING SITES; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, SCID; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031920548     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Longo, D. L. Non-Hodgkin's lymphoma. Curr. Opin. Haematol., 1: 295-302, 1994.
2. Grossbard, M. L., Press, O. W., Appelbaum, F. R., Bernstein, I. D., and Nadler, L. M. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood, 80: 863-878, 1992.
3. Maloney, D. G., Liles, T. M., Czerwinski, D. K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., and Levy, R. Phase I clinical trial using escalating single dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84: 2457-2466, 1994.
4. Henniker, A. J., Bradstock, K. F., Grimsley, P., and Atkinson, M. K. A novel non-lineage antigen on human leucocytes: characterization with two CD-48 monoclonal antibodies. Dis. Markers, 8: 179-190, 1990.
5. Vaughan, H. A., Thompson, C. H., Sparrow, R. L., McKenzie, I. F. C. HuLy-m3-a human leucocyte antigen. Transplantation (Baltimore), 36: 446-450, 1983.
6. Hadam, M. R. N10 Cluster Report: CD48. NK- and non-lineage antigens. Fourth International Workshop and Conference on Human Leucocyte Differentiation Antigens, p. 661-664, 1989.
7. Kato, K., Koyanagi, M., Okada, H., Takanashi, T., Wong, Y. W., Williams, A. F., Okumura, K., and Yagita, H. CD48 is a counter-receptor for mouse CD2 and is involved in T cell activation. J. Exp. Med., 176: 1241-1249, 1992.
8. Arulanandam, A. R. N., Moingeon, P., Concino, M. F., Recny, M. A., Kato, K., Yagita, H., Koyasu, S., and Reinherz, E. L. A soluble multimeric recombinant CD2 protein identifies CD48 as a low affinity ligand for human CD2: divergence of CD2 ligands during the evolution of humans and mice. J. Exp. Med., 177: 1439-1450, 1993.
9. Sandrin, M. S., Mouhtouris, E., Vaughan, H. A., Warren, H. S., and Parish, C. R. CD48 is a low affinity ligand for human CD2. J. Immunol., 151: 4606-4613, 1993.
10. Korinek, V., Stefanova, I., Angelisova, P., Hilgert, I., and Horejsi, V. The human leucocyte antigen CD48 (MEM-102) is closely related to the activation marker Blast-1. Immunogenetics, 33: 108-112, 1991.
11. Vaughau, H. A., Henning, M. M., Purcell, D. F. J., McKenzie, I. F. C., and Sandrin, M. S. The isolation of cDNA clones for CD48. Immunogenetics, 33: 113-117, 1991.
12. Staunton, D. E., and Thorley-Lawson, D. A. Molecular cloning of the lymphocyte activation marker Blast-1. EMBO J., 6: 3695-3701, 1987.
13. Greenaway, S., Henniker, A. J., Walsh, M., and Bradstock, K. F. A pilot clinical trial of two murine monoclonal antibodies fixing human complement in patients with chronic lymphatic leukemia. Leuk. Lymphoma, 13: 323-331, 1994.
14. Harlow, E., and Lane, D. Antibodies. A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbour Laboratory, 1988.
15. Telerman, A., Amson, R. B., Romasco, F., Wybran, J., Galand, P., and Mosselmans, R. Internalization of human T lymphocyte receptors. Eur. J. Immunol., 17: 991-997, 1987.
16. Press, O. W., Hansen, J. A., Farr, A., and Martin, P. J. Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes. Cancer Res., 48: 2249-2257, 1988.
17. Major, S., Rotheberg, K. G., and Maxfield, F. R. Sequestration of GPI-anchored proteins in caveolae trigged by cross-linking. Science (Washington DC), 264: 1948-1951, 1994.
18. Kawata, A., Yoshida, M., Okazaki, M., Yokota, S., Barcos, M., and Seon, B. K. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody. Cancer Res., 54: 2688-2694, 1994.
19. Gretie, G. A., Richardson, J., Tucher, T., Jones, D., Uhr, J. W., and Vitettaz, E. S. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int. J. Cancer, 45: 481-485, 1990.
20. Herlyn, D., and Koprowski, H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. J. Biol. Chem., 79: 4761-4765, 1982.
21. Dyer, M. J. S., Hale, G., Marcus, R., and Waldmann, H. Remission induced in patients with lymphoid malignancies using unconjugated CAMPATH-1 monoclonal antibodies. Leuk. Lymphoma, 2: 179-193, 1990.
22. Dyer, M. J. S., Hale, G., Hayhoe, F. G. J., and Waldmann, H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood, 73: 1431-1439, 1989.
23. Bruggemann, M., Williams, G. T., Bindon, C. I., Clark, M. R., Walker, M. R., Jefferis, R., Waldmann, H., and Neuberger, M. S. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med., 166: 1351-1361, 1987.
24. Greenwood, J., and Clark, M. Effector functions of matched sets of recombinant human IgG subclass antibodies. In: M. Clark (ed.), Antibody Effector Functions, Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man (Section II), p. 85. Nottingham, England: Academic Titles, 1993.
25. Baum, C. M., Weissman, I. L., Tsukamoto, A. S., Buckle, A. M., and Peault, B. Isolation of a candidate human haematopoietic stem-cell population. Proc. Natl. Acad. Sci. USA, 89: 2804, 1992.
26. Thorley-Lawson, D. A., Schooley, R. T., Bhan, A. K., and Nadler, L. M. Epstein-Barr virus superinduces a new human B cell differentiation antigen (Blast 1) expressed on transformed lymphoblasts. Cell, 30: 415-425, 1982.
27. Shin, S. U. Chimeric antibody: potential applications for drug delivery and immunotherapy. Biotherapy, 3: 43-53, 1991.